Target Blood Pressure and Kidney Disease
Authors: Mark J. Sarnak, Andrew S. Levey, Tom Greene
Journal: Annals of Internal Medicine (2005)

Letters16 August 2005Target Blood Pressure and Kidney DiseaseMark J. Sarnak, MD, MS, Andrew S. Levey, MD, and Tom Greene, PhDMark J. Sarnak, MD, MSFrom Tufts-New England Medical Center, Boston, MA 02111, and Cleveland Clinic Foundation, Cleveland, OH 44195.Search for more papers by this author, Andrew S. Levey, MDFrom Tufts-New England Medical Center, Boston, MA 02111, and Cleveland Clinic Foundation, Cleveland, OH 44195.Search for more papers by this author, and Tom Greene, PhDFrom Tufts-New England Medical Center, Boston, MA 02111, and Cleveland Clinic Foundation, Cleveland, OH 44195.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-4-200508160-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Good raises the concern that deaths in our study may have been higher in the group with the lower target blood pressure. It is important to note, however, that the deaths to which Dr. Good refers include only those that occurred before development of kidney failure (see the legend to our Figure 2). Consideration of deaths that occurred only before kidney failure may result in an informative censoring bias. That is, those patients who reach kidney failure first may be more likely to die; however, the deaths that occur after kidney failure are not included in the ...Reference1. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73-87. [PMID: 11453706] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Tufts-New England Medical Center, Boston, MA 02111, and Cleveland Clinic Foundation, Cleveland, OH 44195.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAngiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease Tazeen H. Jafar , Christopher H. Schmid , Marcia Landa , Ioannis Giatras , Robert Toto , Giuseppe Remuzzi , Giuseppe Maschio , Barry M. Brenner , Annelise Kamper , Pietro Zucchelli , Gavin Becker , Andres Himmelmann , Kym Bannister , Paul Landais , Shahnaz Shahinfar , Paul E. de Jong , Dick de Zeeuw , Joseph Lau , Andrew S. Levey , and The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak , Tom Greene , Xuelei Wang , Gerald Beck , John W. Kusek , Allan J. Collins , and Andrew S. Levey Target Blood Pressure and Kidney Disease Chester B. Good Target Blood Pressure and Kidney Disease Yujiro Kida Metrics 16 August 2005Volume 143, Issue 4Page: 311KeywordsACE inhibitorsBlood groupsBlood pressureDeath ratesHypotensionRegression analysisRenal diseasesRenal failure ePublished: 16 August 2005 Issue Published: 16 August 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...